Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza, UCB Sign Antibody Pact

Production deal spotlights emerging field of antibody fragments

by Michael McCoy
May 23, 2005 | A version of this story appeared in Volume 83, Issue 21

BIOTECHNOLOGY

MOBILE
[+]Enlarge
Credit: LONZA PHOTO
Lonza installed this 200-L microbial fermentor in Visp, Switzerland, last year.
Credit: LONZA PHOTO
Lonza installed this 200-L microbial fermentor in Visp, Switzerland, last year.

Lonza and UCB have signed a long-term agreement under which Lonza will manufacture active pharmaceutical ingredients based on PEGylated antibody fragments for UCB. Pro duction will take place at a $165 million microbial fermentation facility that Lonza says it will build in Visp, Switzerland.

The deal highlights growth in the relatively new fields of antibody fragments and single-chain antibodies. Both can be manufactured microbially, rather than with the mammalian cell culture technique that must be used to produce typical monoclonal antibodies.

According to Kevin Johnson, general partner at U.K.-based Ash Biotech Consulting, microbial production can save time and money for biotech firms developing antibodies. Therapeutically, antibody fragments penetrate tissue better than whole antibodies and are "immunologically silent," Johnson points out.

UCB says that Cimzia, its antibody fragment now in Phase III clinical trials for Crohn's disease and rheumatoid arthritis, is the most advanced product using this technology. Other antibody fragments are in the new-drug pipeline, however, prompting investment in microbial fermentation production capacity.

Lonza says it will build two 15,000-L fermentation trains to go into operation late in 2006. A portion of the capacity will be dedicated to UCB for six years.

Boehringer Ingelheim, meanwhile, opened a $100 million microbial fermentation plant in Austria last month, and Wacker-Chemie recently announced plans to invest up to $60 million in microbial contract manufacturing. Wacker said it chose to focus on microbial fermentation, in part because it anticipates demand for antibody fragments.

Johnson says antibody fragments are complementing, not replacing, whole antibodies in the biotechnology industry's labs. "Antibodies are on a roll," he says, "and this technology is going to maintain the trajectory or increase it."

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.